

ORAL PRESENTATION

Open Access

Gene Therapy for *LMNA*-related Congenital Muscular Dystrophy (L-CMD) by Trans-Splicing

Feriel Azibani*, Anne T Bertrand

From 1st French-Italian meeting on laminopathies and other nuclear envelope-related diseases
Marseille, France. 15-16 January 2015

LMNA-related Congenital Muscular Dystrophy (L-CMD) is a rare genetic disorder characterized by the onset of selective axial weakness and wasting in the first year of life with limited motor achievements, associated with multiple severe contractures and frequent respiratory failure requiring early ventilatory support. We identified heterozygous *de novo* mutations in *LMNA*, encoding lamins A/C, as responsible for this sub-group of CMD in which no therapeutic treatment is available[1]. Lamins A/C are nuclear envelope proteins, ubiquitously expressed in all post mitotic cells, which play essential roles in the nucleus structure and in the regulation of gene expression. We generated the first Knock-In mouse model of L-CMD (KI-*Lmna*^{delK32}) reproducing a *LMNA* mutation identified in L-CMD patients. Homozygous mice die within the first 3 weeks of life from striated muscles maturation delay and severe metabolic defects [2]. Heterozygous mice develop an isolated dilated cardiomyopathy and die by one year of age[3]. We aim to assess the possibility of *LMNA*-mRNA repair by spliceosome-mediated RNA trans-splicing (SMarT) as a potential therapeutic approach for L-CMD. This gene therapy strategy will allow inhibition of mutated *LMNA* transcript expression for the benefit of corresponding wild type transcripts. We developed 5'-RNA pre-trans-splicing molecules (PTM) capable of repairing the murine *LMNA* transcripts. Efficiency of these PTM was assessed *in vitro* in C2C12 cells and *in vivo* using Adeno-Associated Virus (AAV) transduction in *tibialis anterior* of WT mice. We will now determine the ability of the best PTM to restore normal muscular phenotype, *in vitro* in KI myoblasts/myotubes and *in vivo* after injection of AAV-PTM vectors in new born homozygous and adult heterozygous

mice. Histological and metabolic parameters will be monitored to evaluate the degree of phenotype rescue.

Published: 11 November 2015

References

1. Quijano-Roy S, Mbieleu B, Bonnemann CG, Jeannet PY, Colomer J, Clarke NF, et al: **De novo *LMNA* mutations cause a new form of congenital muscular dystrophy.** *Annals of neurology* 2008, **64**(2):177-86.
2. Bertrand AT, Renou L, Papadopoulos A, Beuvin M, Lacene E, Massart C, et al: **DelK32-lamin A/C has abnormal location and induces incomplete tissue maturation and severe metabolic defects leading to premature death.** *Human molecular genetics* 2012, **21**(5):1037-48.
3. Cattin ME, Bertrand AT, Schlossarek S, Le Bihan MC, Skov Jensen S, Neuber C, et al: **Heterozygous *Lmna*^{delK32} mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity.** *Human molecular genetics* 2013, **22**(15):3152-64.

doi:10.1186/1750-1172-10-S2-O11

Cite this article as: Azibani and Bertrand: Gene Therapy for *LMNA*-related Congenital Muscular Dystrophy (L-CMD) by Trans-Splicing. *Orphanet Journal of Rare Diseases* 2015 **10**(Suppl 2):O11.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



* Correspondence: f.azibani@institut-myologie.org
Sorbonne Universités, UPMC Univ Paris 06, INSERM UMR5974, CNRS FRE3617,
Center for Research in Myology, Paris, France